Evolving methodology of national tobacco control investment cases.


Journal

Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612

Informations de publication

Date de publication:
02 May 2024
Historique:
received: 15 08 2023
accepted: 19 01 2024
medline: 3 5 2024
pubmed: 3 5 2024
entrez: 2 5 2024
Statut: epublish

Résumé

This article describes an investment case methodology for tobacco control that was applied in 36 countries between 2017 and 2022. The WHO Framework Convention on Tobacco Control (FCTC) investment cases compared two scenarios: a base case that calculated the tobacco-attributable mortality, morbidity and economic costs with status quo tobacco control, and an intervention scenario that described changes in those same outcomes from fully implementing and enforcing a variety of proven, evidence-based tobacco control policies and interventions. Health consequences included the tobacco-attributable share of mortality and morbidity from 38 diseases. The healthcare expenditures and the socioeconomic costs from the prevalence of those conditions were combined to calculate the total losses due to tobacco. The monetised benefits of improvements in health resulting from tobacco control implementation were compared with costs of expanding tobacco control to assess returns on investment in each country. An institutional and context analysis assessed the political and economic dimensions of tobacco control in each context. We applied a rigorous yet flexible methodology in 36 countries over 5 years. The replicable model and framework may be used to inform development of tobacco control cases in countries worldwide. Investment cases constitute a tool that development partners and advocates have demanded in even greater numbers. The economic argument for tobacco control provided by this set of country-contextualised analyses can be a strong tool for policy change.

Sections du résumé

BACKGROUND BACKGROUND
This article describes an investment case methodology for tobacco control that was applied in 36 countries between 2017 and 2022.
METHODS METHODS
The WHO Framework Convention on Tobacco Control (FCTC) investment cases compared two scenarios: a base case that calculated the tobacco-attributable mortality, morbidity and economic costs with status quo tobacco control, and an intervention scenario that described changes in those same outcomes from fully implementing and enforcing a variety of proven, evidence-based tobacco control policies and interventions. Health consequences included the tobacco-attributable share of mortality and morbidity from 38 diseases. The healthcare expenditures and the socioeconomic costs from the prevalence of those conditions were combined to calculate the total losses due to tobacco. The monetised benefits of improvements in health resulting from tobacco control implementation were compared with costs of expanding tobacco control to assess returns on investment in each country. An institutional and context analysis assessed the political and economic dimensions of tobacco control in each context.
RESULTS RESULTS
We applied a rigorous yet flexible methodology in 36 countries over 5 years. The replicable model and framework may be used to inform development of tobacco control cases in countries worldwide.
CONCLUSION CONCLUSIONS
Investment cases constitute a tool that development partners and advocates have demanded in even greater numbers. The economic argument for tobacco control provided by this set of country-contextualised analyses can be a strong tool for policy change.

Identifiants

pubmed: 38697658
pii: tc-2023-058336
doi: 10.1136/tc-2023-058336
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

s10-s16

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Rachel Nugent (R)

Department of Global Health, University of Washington, Seattle, Washington, USA rnugent2@uw.edu.
RTI International, Research Triangle Park, North Carolina, USA.

Brian Hutchinson (B)

RTI International, Research Triangle Park, North Carolina, USA.

Nathan Mann (N)

RTI International, Research Triangle Park, North Carolina, USA.

Carrie Ngongo (C)

RTI International, Research Triangle Park, North Carolina, USA.

Garrison Spencer (G)

RTI International, Research Triangle Park, North Carolina, USA.

Daniel Grafton (D)

United Nations Development Programme, Istanbul, Turkey.

Roy Small (R)

HIV, Health and Development Group, United Nations Development Programme, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH